Janice M. Huss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Janice M. Huss has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Angelica Hamilton
Department of Molecular and Cellular Endocrinology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA
2 shared publicationsJennifer Murray
Department of Diabetes and Metabolic Diseases Research, Division of Cellular and Molecular Diabetes Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA
2 shared publicationsJohan Auwerx
Ecole Polytechnique Fédérale de Lausanne Laboratory of Integrative and Systems Physiology Lausanne Switzerland
2 shared publicationsBarry M. Forman
Department of Diabetes and Metabolic Diseases Research, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
1 shared publication- Donna D. Yu
Department of Diabetes and Metabolic Diseases Research, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
1 shared publication - Gal Lenz
Department of Cancer Biology, City of Hope, CA 91010, USA
1 shared publication
Latest Publications
- 1 November 2018
- Published by Elsevier in General and Comparative Endocrinology
- Vol. 268, 110-120
Conserved transcriptional activity and ligand responsiveness of avian PPARs: Potential role in regulating lipid metabolism in mirgratory birds
- 1 November 2018
- Published by Elsevier in General and Comparative Endocrinology
- Vol. 268, 110-120
Conserved transcriptional activity and ligand responsiveness of avian PPARs: Potential role in regulating lipid metabolism in mirgratory birds
- 28 February 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (5) , 1216-1226
t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells
Purpose: Increased glycolysis and glucose dependence is a hallmark of malignancy that enables tumors to maximize cell proliferation. In HER2+ cancers, an increase in glycolytic capacity is associated with trastuzumab resistance. IGF-1R activation and t-Darpp overexpression both confer trastuzumab resistance in breast cancer. We therefore investigated a role for IGF-1R and t-Darpp in regulating glycolytic capacity in HER2+ breast cancers. Experimental Design: We examined the relationship between t-Darpp and IGF-1R expression in breast tumors and their respective relationships with patient survival. To assess t-Darpp's metabolic effects, we used the Seahorse flux analyzer to measure glucose metabolism in trastuzumab-resistant SK-BR-3 cells (SK.HerR) that have high endogenous t-Darpp levels and SK.tDrp cells that stably overexpress exogenous t-Darpp. To investigate t-Darpp's mechanism of action, we evaluated t-Darpp:IGF-1R complexes by coimmunoprecipitation and proximity ligation assays. We used pathway-specific inhibitors to study the dependence of t-Darpp effects on IGF-1R signaling. We used siRNA knockdown to determine whether glucose reliance in SK.HerR cells was mediated by t-Darpp. Results: In breast tumors, PPP1R1B mRNA levels were inversely correlated with IGF-1R mRNA levels and directly associated with shorter overall survival. t-Darpp overexpression was sufficient to increase glucose metabolism in SK.tDrp cells and essential for the glycolytic phenotype of SK.HerR cells. Recombinant t-Darpp stimulated glucose uptake, glycolysis, and IGF-1R–Akt signaling in SK-BR-3 cells. Finally, t-Darpp stimulated IGF-1R heterodimerization with ErbB receptors and required IGF-1R signaling to confer its metabolic effects. Conclusions: t-Darpp activates IGF-1R signaling through heterodimerization with EGFR and HER2 to stimulate glycolysis and confer trastuzumab resistance. Clin Cancer Res; 24(5); 1216–26. ©2017 AACR.
- 28 February 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (5) , 1216-1226
t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells
Purpose: Increased glycolysis and glucose dependence is a hallmark of malignancy that enables tumors to maximize cell proliferation. In HER2+ cancers, an increase in glycolytic capacity is associated with trastuzumab resistance. IGF-1R activation and t-Darpp overexpression both confer trastuzumab resistance in breast cancer. We therefore investigated a role for IGF-1R and t-Darpp in regulating glycolytic capacity in HER2+ breast cancers. Experimental Design: We examined the relationship between t-Darpp and IGF-1R expression in breast tumors and their respective relationships with patient survival. To assess t-Darpp's metabolic effects, we used the Seahorse flux analyzer to measure glucose metabolism in trastuzumab-resistant SK-BR-3 cells (SK.HerR) that have high endogenous t-Darpp levels and SK.tDrp cells that stably overexpress exogenous t-Darpp. To investigate t-Darpp's mechanism of action, we evaluated t-Darpp:IGF-1R complexes by coimmunoprecipitation and proximity ligation assays. We used pathway-specific inhibitors to study the dependence of t-Darpp effects on IGF-1R signaling. We used siRNA knockdown to determine whether glucose reliance in SK.HerR cells was mediated by t-Darpp. Results: In breast tumors, PPP1R1B mRNA levels were inversely correlated with IGF-1R mRNA levels and directly associated with shorter overall survival. t-Darpp overexpression was sufficient to increase glucose metabolism in SK.tDrp cells and essential for the glycolytic phenotype of SK.HerR cells. Recombinant t-Darpp stimulated glucose uptake, glycolysis, and IGF-1R–Akt signaling in SK-BR-3 cells. Finally, t-Darpp stimulated IGF-1R heterodimerization with ErbB receptors and required IGF-1R signaling to confer its metabolic effects. Conclusions: t-Darpp activates IGF-1R signaling through heterodimerization with EGFR and HER2 to stimulate glycolysis and confer trastuzumab resistance. Clin Cancer Res; 24(5); 1216–26. ©2017 AACR.
- 1 March 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (5) , 1585-1599
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ
- 1 March 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (5) , 1585-1599
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ
- 1 September 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1852 (9) , 1912-1927
Constitutive activities of estrogen-related receptors: Transcriptional regulation of metabolism by the ERR pathways in health and disease
- 1 September 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1852 (9) , 1912-1927
Constitutive activities of estrogen-related receptors: Transcriptional regulation of metabolism by the ERR pathways in health and disease
- Open Access
- 25 November 2013
- Published by Wiley in The FASEB Journal
- Vol. 28 (3) , 1082-1097
Estrogen‐related receptor‐α (ERRα) deficiency in skeletal muscle impairs regeneration in response to injury
The estrogen‐related receptor‐α (ERRα) regulates mitochondrial biogenesis and glucose and fatty acid oxidation during differentiation in skeletal myocytes. However, whether ERRα controls metabolic remodeling during skeletal muscle regeneration in vivo is unknown. We characterized the time course of skeletal muscle regeneration in wild‐type ( M‐ERRα WT ) and muscle‐specific ERR α –/– ( M‐ERR α –/– ) mice after injury by intramuscular cardiotoxin injection. M‐ERRα –/‐ mice exhibited impaired regeneration characterized by smaller myofibers with increased centrally localized nuclei and reduced mitochondrial density and cytochrome oxidase and citrate synthase activities relative to M‐ERRαWT. Transcript levels of mitochondrial transcription factor A, nuclear respiratory factor‐2α, and peroxisome proliferator‐activated receptor (PPAR)‐γ coactivator (PGC)‐1β, were downregulated in the M‐ERR α –/– muscles at the onset of myogenesis. Furthermore, coincident with delayed myofiber recovery, we observed reduced muscle ATP content (–45% vs. M‐ERRαWT ) and enhanced AMP‐activated protein kinase (AMPK) activation in M‐ERR α –/– muscle. We subsequently demonstrated that pharmacologic postinjury AMPK activation was sufficient to delay muscle regeneration in WT mice. AMPK activation induced ERRα transcript expression in M‐ERRαWT muscle and in C2C12 myotubes through induction of the Esrra promoter, indicating that ERRα may control gene regulation downstream of the AMPK pathway. Collectively, these results suggest that ERRα deficiency during muscle regeneration impairs recovery of mitochondrial energetic capacity and perturbs AMPK activity, resulting in delayed myofiber repair.—LaBarge, S., McDonald, M., Smith‐Powell, L., Auwerx, J., Huss, J. M. Estrogen‐related receptor‐α (ERRα) deficiency in skeletal muscle impairs regeneration in response to injury. FASEB J. 28, 1082–1097 (2014). www.fasebj.org
- 25 November 2013
- Published by Wiley in The FASEB Journal
- Vol. 28 (3) , 1082-1097
Open AccessEstrogen‐related receptor‐α (ERRα) deficiency in skeletal muscle impairs regeneration in response to injury
The estrogen‐related receptor‐α (ERRα) regulates mitochondrial biogenesis and glucose and fatty acid oxidation during differentiation in skeletal myocytes. However, whether ERRα controls metabolic remodeling during skeletal muscle regeneration in vivo is unknown. We characterized the time course of skeletal muscle regeneration in wild‐type ( M‐ERRα WT ) and muscle‐specific ERR α –/– ( M‐ERR α –/– ) mice after injury by intramuscular cardiotoxin injection. M‐ERRα –/‐ mice exhibited impaired regeneration characterized by smaller myofibers with increased centrally localized nuclei and reduced mitochondrial density and cytochrome oxidase and citrate synthase activities relative to M‐ERRαWT. Transcript levels of mitochondrial transcription factor A, nuclear respiratory factor‐2α, and peroxisome proliferator‐activated receptor (PPAR)‐γ coactivator (PGC)‐1β, were downregulated in the M‐ERR α –/– muscles at the onset of myogenesis. Furthermore, coincident with delayed myofiber recovery, we observed reduced muscle ATP content (–45% vs. M‐ERRαWT ) and enhanced AMP‐activated protein kinase (AMPK) activation in M‐ERR α –/– muscle. We subsequently demonstrated that pharmacologic postinjury AMPK activation was sufficient to delay muscle regeneration in WT mice. AMPK activation induced ERRα transcript expression in M‐ERRαWT muscle and in C2C12 myotubes through induction of the Esrra promoter, indicating that ERRα may control gene regulation downstream of the AMPK pathway. Collectively, these results suggest that ERRα deficiency during muscle regeneration impairs recovery of mitochondrial energetic capacity and perturbs AMPK activity, resulting in delayed myofiber repair.—LaBarge, S., McDonald, M., Smith‐Powell, L., Auwerx, J., Huss, J. M. Estrogen‐related receptor‐α (ERRα) deficiency in skeletal muscle impairs regeneration in response to injury. FASEB J. 28, 1082–1097 (2014). www.fasebj.org
- Open Access
- 4 October 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (1) , 135-150
Impaired myogenesis in estrogen‐related receptor γ (ERRγ)‐deficient skeletal myocytes due to oxidative stress
Specialized contractile function and increased mitochondrial number and oxidative capacity are hallmark features of myocyte differentiation. The estrogen‐related receptors (ERRs) can regulate mitochondrial biogenesis or mitochondrial enzyme expression in skeletal muscle, suggesting that ERRs may have a role in promoting myogenesis. Therefore, we characterized myogenic programs in primary myocytes isolated from wild‐type (M‐ERRγWT) and muscle‐specific ERRγ –/– (M‐ERRγ –/– ) mice. Myotube maturation and number were decreased throughout differentiation in M‐ERRγ –/– primary myocytes, resulting in myotubes with reduced mitochondrial content and sarcomere assembly. Compared with M‐ERRγWT myocytes at the same differentiation stage, the glucose oxidation rate was reduced by 30% in M‐ERRγ –/– myotubes, while medium‐chain fatty acid oxidation was increased by 34% in M‐ERRγ –/– myoblasts and 36% in M‐ERRγ –/– myotubes. Concomitant with increased reliance on mitochondrial β‐oxidation, H 2 O 2 production was significantly increased by 40% in M‐ERRγ –/– myoblasts and 70% in M‐ERRγ –/– myotubes compared to M‐ERRγWT myocytes. ROS activation of FoxO and NF‐κB and their downstream targets, atrogin‐1 and MuRF1, was observed in M‐ERRγ –/– myocytes. The antioxidant N ‐acetyl cysteine rescued myotube formation and atrophy gene induction in M‐ERRγ –/– myocytes. These results suggest that loss of ERRγ causes metabolic defects and oxidative stress that impair myotube formation through activation of skeletal muscle atrophy pathways.—Murray, J., Auwerx, J., Huss, J. M. Impaired myogenesis in estrogen‐related receptor γ (ERRγ)‐deficient skeletal myocytes due to oxidative stress. FASEB J. 27, 135–150 (2013). www.fasebj.org
- 4 October 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (1) , 135-150
Open AccessImpaired myogenesis in estrogen‐related receptor γ (ERRγ)‐deficient skeletal myocytes due to oxidative stress
Specialized contractile function and increased mitochondrial number and oxidative capacity are hallmark features of myocyte differentiation. The estrogen‐related receptors (ERRs) can regulate mitochondrial biogenesis or mitochondrial enzyme expression in skeletal muscle, suggesting that ERRs may have a role in promoting myogenesis. Therefore, we characterized myogenic programs in primary myocytes isolated from wild‐type (M‐ERRγWT) and muscle‐specific ERRγ –/– (M‐ERRγ –/– ) mice. Myotube maturation and number were decreased throughout differentiation in M‐ERRγ –/– primary myocytes, resulting in myotubes with reduced mitochondrial content and sarcomere assembly. Compared with M‐ERRγWT myocytes at the same differentiation stage, the glucose oxidation rate was reduced by 30% in M‐ERRγ –/– myotubes, while medium‐chain fatty acid oxidation was increased by 34% in M‐ERRγ –/– myoblasts and 36% in M‐ERRγ –/– myotubes. Concomitant with increased reliance on mitochondrial β‐oxidation, H 2 O 2 production was significantly increased by 40% in M‐ERRγ –/– myoblasts and 70% in M‐ERRγ –/– myotubes compared to M‐ERRγWT myocytes. ROS activation of FoxO and NF‐κB and their downstream targets, atrogin‐1 and MuRF1, was observed in M‐ERRγ –/– myocytes. The antioxidant N ‐acetyl cysteine rescued myotube formation and atrophy gene induction in M‐ERRγ –/– myocytes. These results suggest that loss of ERRγ causes metabolic defects and oxidative stress that impair myotube formation through activation of skeletal muscle atrophy pathways.—Murray, J., Auwerx, J., Huss, J. M. Impaired myogenesis in estrogen‐related receptor γ (ERRγ)‐deficient skeletal myocytes due to oxidative stress. FASEB J. 27, 135–150 (2013). www.fasebj.org
- 1 September 2011
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 301 (3) , C630-C645
Estrogen-related receptor α regulates skeletal myocyte differentiation via modulation of the ERK MAP kinase pathway
Myocyte differentiation involves complex interactions between signal transduction pathways and transcription factors. The estrogen-related receptors (ERRs) regulate energy substrate uptake, mitochondrial respiration, and biogenesis and may target structural gene programs in striated muscle. However, ERRα's role in regulating myocyte differentiation is not known. ERRα and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) are coordinately upregulated with metabolic and skeletal muscle-specific genes early in myogenesis. We analyzed effects of ERRα overexpression and loss of function in myogenic models. In C2C12 myocytes ERRα overexpression accelerated differentiation, whereas XCT790 treatment delayed myogenesis and resulted in myotubes with fewer mitochondria and disorganized sarcomeres. ERRα−/− primary myocytes showed delayed myogenesis, resulting in structurally immature myotubes with reduced sarcomeric assembly and mitochondrial function. However, sarcomeric and metabolic gene expression was unaffected or upregulated in ERRα−/− cells. Instead, ERRα−/− myocytes exhibited aberrant ERK activation early in myogenesis, consistent with delayed myotube formation. XCT790 treatment also increased ERK phosphorylation in C2C12, whereas ERRα overexpression decreased early ERK activation, consistent with the opposing effects of these treatments on differentiation. The transient induction of MAP kinase phosphatase-1 (MKP-1), which mediates ERK dephosphorylation at the onset of myogenesis, was lost in ERRα−/− myocytes and in XCT790-treated C2C12. The ERRα-PGC-1α complex activates the Dusp1 gene, which encodes MKP-1, and ERRα occupies the proximal 5′ regulatory region during early differentiation in C2C12 myocytes. Finally, treatment of ERRα−/− myocytes with MEK inhibitors rescued normal ERK signaling and myogenesis. Collectively, these data demonstrate that ERRα is required for normal skeletal myocyte differentiation via modulation of MAP kinase signaling.
- 1 September 2011
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 301 (3) , C630-C645
Estrogen-related receptor α regulates skeletal myocyte differentiation via modulation of the ERK MAP kinase pathway
Myocyte differentiation involves complex interactions between signal transduction pathways and transcription factors. The estrogen-related receptors (ERRs) regulate energy substrate uptake, mitochondrial respiration, and biogenesis and may target structural gene programs in striated muscle. However, ERRα's role in regulating myocyte differentiation is not known. ERRα and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) are coordinately upregulated with metabolic and skeletal muscle-specific genes early in myogenesis. We analyzed effects of ERRα overexpression and loss of function in myogenic models. In C2C12 myocytes ERRα overexpression accelerated differentiation, whereas XCT790 treatment delayed myogenesis and resulted in myotubes with fewer mitochondria and disorganized sarcomeres. ERRα−/− primary myocytes showed delayed myogenesis, resulting in structurally immature myotubes with reduced sarcomeric assembly and mitochondrial function. However, sarcomeric and metabolic gene expression was unaffected or upregulated in ERRα−/− cells. Instead, ERRα−/− myocytes exhibited aberrant ERK activation early in myogenesis, consistent with delayed myotube formation. XCT790 treatment also increased ERK phosphorylation in C2C12, whereas ERRα overexpression decreased early ERK activation, consistent with the opposing effects of these treatments on differentiation. The transient induction of MAP kinase phosphatase-1 (MKP-1), which mediates ERK dephosphorylation at the onset of myogenesis, was lost in ERRα−/− myocytes and in XCT790-treated C2C12. The ERRα-PGC-1α complex activates the Dusp1 gene, which encodes MKP-1, and ERRα occupies the proximal 5′ regulatory region during early differentiation in C2C12 myocytes. Finally, treatment of ERRα−/− myocytes with MEK inhibitors rescued normal ERK signaling and myogenesis. Collectively, these data demonstrate that ERRα is required for normal skeletal myocyte differentiation via modulation of MAP kinase signaling.